ArticlePLoS pathogens2020
Broad dengue neutralization in mosquitoes expressing an engineered antibody.
Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 98 citations in OpenAlex.
- Advances in CRISPR gene drives for mosquito population control.Current opinion in microbiology · 2026Review
- SSA-like and MMEJ-like recombination events in a transgenic construct with in-cis programmed self-eliminating components in different E. coli strains.BMC research notes · 2026Article
- In silico identification of anticancer flavonoids as dengue virus replication inhibitors: a molecular docking and simulation approach.Journal of molecular modeling · 2025Article
- Performance of two low-threshold population replacement gene drives in cage populations of the yellow fever mosquito, Aedes aegypti.PLoS genetics · 2025Article
- Engineered antibody-mediated broad-spectrum suppression of human arboviruses in the Aedes aegypti vector.Communications biology · 2025Article
- AustralianEmerging microbes & infections · 2024Article
- Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.Nature reviews. Immunology · 2024Review
- Dengue: A focused review for the emergency clinician.The American journal of emergency medicine · 2024Review
- Advances and challenges in synthetic biology for mosquito control.Trends in parasitology · 2024Review
- Evaluating the specificity of flavivirus proteases in Aedes aegypti cells for dengue virus 2-derived cleavage sites.PloS one · 2024Article
- Engineered Antiviral Sensor Targets Infected Mosquitoes.The CRISPR journal · 2023Article
- Manipulating the Destiny of Wild Populations Using CRISPR.Annual review of genetics · 2023Review
- CRISPR-based gene drives generate super-Mendelian inheritance in the disease vector Culex quinquefasciatus.Nature communications · 2023Article
- Mimicking superinfection exclusion disrupts alphavirus infection and transmission in the yellow fever mosquitoProceedings of the National Academy of Sciences of the United States of America · 2023Article
- CRISPR-based gene drives generate super-Mendelian inheritance in the disease vectorbioRxiv : the preprint server for biology · 2023Article
- Article
- Transgene-induced cell death following dengue-2 virus infection in Aedes aegypti.Scientific reports · 2023Article
- Article
- Virology under the Microscope-a Call for Rational Discourse.Journal of virology · 2023Article
- Engineered Antiviral Sensor Targets Infected Mosquitoes.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
With dengue virus (DENV) becoming endemic in tropical and subtropical regions worldwide, there is a pressing global demand for effective strategies to control the mosquitoes that spread this disease. Recent advances in genetic engineering technologies have made it possible to create mosquitoes with reduced vector competence, limiting their ability to acquire and transmit pathogens. Here we describe the development of Aedes aegypti mosquitoes synthetically engineered to impede vector competence to DENV. These mosquitoes express a gene encoding an engineered single-chain variable fragment derived from a broadly neutralizing DENV human monoclonal antibody and have significantly reduced viral infection, dissemination, and transmission rates for all four major antigenically distinct DENV serotypes. Importantly, this is the first engineered approach that targets all DENV serotypes, which is crucial for effective disease suppression. These results provide a compelling route for developing effective genetic-based DENV control strategies, which could be extended to curtail other arboviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.